Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Ronac Mamtani et al.|The Lancet Oncology|2021Cited by 645
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset DiabetesBen Boursi, Yu‐Xiao Yang, Brian S. Finkelman et al.|Gastroenterology|2016Cited by 193
Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score–matched analysisBrett L. Ecker, Robert E. Roses, Matthew T. McMillan et al.|Cancer|2015Cited by 115
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional StudyKim A. Reiss, David E. Kaplan, Shun Yu et al.|Journal of Clinical Oncology|2017Cited by 98
Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaErin M. Bange, Ronac Mamtani, Abigail Doucette et al.|JCO Oncology Practice|2020Cited by 64